Lycopene in the prevention of prostate cancer

J Soc Integr Oncol. Winter 2008;6(1):29-36.

Abstract

Based on the evidence from epidemiologic, animal, and in vitro data and human clinical trials, it is evident that lycopene, a non-provitamin A carotenoid, is a promising agent for prostate cancer chemoprevention. It is also clear that the form of lycopene used (purified versus food sources), dose of lycopene and concomitant use with other carotenoids and antioxidants, duration of exposure, specific target populations, and stage of disease appear to play a major role in determining agonistic or antagonistic effects. Based on our review, there is enough evidence to warrant use of lycopene in phase I and II clinical trials to examine its safety and efficacy as a potential chemopreventive agent for prostate cancer. The objective of this article is to review this evidence from epidemiologic, animal, in vitro, and clinical trials and provide the need and rationale to examine further the role of lycopene for prostate cancer prevention.

Publication types

  • Review

MeSH terms

  • Animals
  • Anticarcinogenic Agents / therapeutic use*
  • Carotenoids / therapeutic use*
  • Clinical Trials as Topic
  • Humans
  • Lycopene
  • Male
  • Prostatic Neoplasms / epidemiology
  • Prostatic Neoplasms / prevention & control*

Substances

  • Anticarcinogenic Agents
  • Carotenoids
  • Lycopene